We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Exploring Analyst Estimates for Merck (MRK) Q1 Earnings, Beyond Revenue and EPS
Read MoreHide Full Article
Analysts on Wall Street project that Merck (MRK - Free Report) will announce quarterly loss of -$1.51 per share in its forthcoming report, representing a decline of 168% year over year. Revenues are projected to reach $15.9 billion, increasing 2.4% from the same quarter last year.
The consensus EPS estimate for the quarter has been revised 18.4% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
That said, let's delve into the average estimates of some Merck metrics that Wall Street analysts commonly model and monitor.
Based on the collective assessment of analysts, 'Sales- Vaccines- Vaxneuvance' should arrive at $220.75 million. The estimate indicates a year-over-year change of -4%.
The consensus estimate for 'Sales- Oncology- Welireg' stands at $192.28 million. The estimate points to a change of +40.4% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Sales- Oncology- Keytruda' of $7.73 billion. The estimate points to a change of +7.3% from the year-ago quarter.
It is projected by analysts that the 'Sales- Animal health' will reach $1.67 billion. The estimate indicates a year-over-year change of +5.4%.
Analysts predict that the 'Sales- Hospital Acute Care- Bridion - U.S.' will reach $359.36 million. The estimate suggests a change of -4.9% year over year.
Analysts' assessment points toward 'Sales- Oncology- Keytruda - International' reaching $3.13 billion. The estimate suggests a change of +8% year over year.
The consensus among analysts is that 'Sales- Diabetes- Janumet - U.S.' will reach $53.77 million. The estimate indicates a year-over-year change of -17.3%.
The average prediction of analysts places 'Sales- Oncology- Alliance revenue- Lynparza - U.S.' at $149.70 million. The estimate suggests a change of +3.2% year over year.
According to the collective judgment of analysts, 'Sales- Oncology- Alliance revenue- Lynparza - International' should come in at $178.43 million. The estimate points to a change of +6.2% from the year-ago quarter.
Analysts forecast 'Sales- Oncology- Alliance revenue- Lenvima - U.S.' to reach $155.51 million. The estimate suggests a change of -16.4% year over year.
The combined assessment of analysts suggests that 'Sales- Oncology- Alliance revenue- Lenvima - International' will likely reach $75.77 million. The estimate points to a change of +5.2% from the year-ago quarter.
Analysts expect 'Sales- Hospital Acute Care- Zerbaxa - U.S.' to come in at $43.46 million. The estimate suggests a change of +3.5% year over year.
Over the past month, shares of Merck have returned -6.5% versus the Zacks S&P 500 composite's +9.3% change. Currently, MRK carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Exploring Analyst Estimates for Merck (MRK) Q1 Earnings, Beyond Revenue and EPS
Analysts on Wall Street project that Merck (MRK - Free Report) will announce quarterly loss of -$1.51 per share in its forthcoming report, representing a decline of 168% year over year. Revenues are projected to reach $15.9 billion, increasing 2.4% from the same quarter last year.
The consensus EPS estimate for the quarter has been revised 18.4% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
That said, let's delve into the average estimates of some Merck metrics that Wall Street analysts commonly model and monitor.
Based on the collective assessment of analysts, 'Sales- Vaccines- Vaxneuvance' should arrive at $220.75 million. The estimate indicates a year-over-year change of -4%.
The consensus estimate for 'Sales- Oncology- Welireg' stands at $192.28 million. The estimate points to a change of +40.4% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Sales- Oncology- Keytruda' of $7.73 billion. The estimate points to a change of +7.3% from the year-ago quarter.
It is projected by analysts that the 'Sales- Animal health' will reach $1.67 billion. The estimate indicates a year-over-year change of +5.4%.
Analysts predict that the 'Sales- Hospital Acute Care- Bridion - U.S.' will reach $359.36 million. The estimate suggests a change of -4.9% year over year.
Analysts' assessment points toward 'Sales- Oncology- Keytruda - International' reaching $3.13 billion. The estimate suggests a change of +8% year over year.
The consensus among analysts is that 'Sales- Diabetes- Janumet - U.S.' will reach $53.77 million. The estimate indicates a year-over-year change of -17.3%.
The average prediction of analysts places 'Sales- Oncology- Alliance revenue- Lynparza - U.S.' at $149.70 million. The estimate suggests a change of +3.2% year over year.
According to the collective judgment of analysts, 'Sales- Oncology- Alliance revenue- Lynparza - International' should come in at $178.43 million. The estimate points to a change of +6.2% from the year-ago quarter.
Analysts forecast 'Sales- Oncology- Alliance revenue- Lenvima - U.S.' to reach $155.51 million. The estimate suggests a change of -16.4% year over year.
The combined assessment of analysts suggests that 'Sales- Oncology- Alliance revenue- Lenvima - International' will likely reach $75.77 million. The estimate points to a change of +5.2% from the year-ago quarter.
Analysts expect 'Sales- Hospital Acute Care- Zerbaxa - U.S.' to come in at $43.46 million. The estimate suggests a change of +3.5% year over year.
View all Key Company Metrics for Merck here>>>Over the past month, shares of Merck have returned -6.5% versus the Zacks S&P 500 composite's +9.3% change. Currently, MRK carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .